The study of human embryonic stem cells (hESCs) and Induced Pluripotent Stem Cells (iPSC) and its differentiation into specific lineages provides an extraordinary opportunity to study the cellular/molecular mechanisms regulating pluripotency and differentiation. It also offers a potentially unlimited source of numerous cell types for drug screening and cell-based therapies.
Recent developments in the field have demonstrated the ability to reprogram adult human cells to an ES cell-like state using only three or four defined genes. This allows the derivation of patient-specific hiPS cell lines without the major ethical barriers associated with transfer of adult cell nuclei into oocytes. Typically, we work with investigators with the development of protocols for the creation of novel iPS cell lines and their differentiation. Learn more about our unique approach, capabilities, and pricing.
Our expertise and services include:
- Generating induced pluripotent stem cells using the latest transgene-free Sendai Virus and mRNA/micro RNA technology.
- Undifferentiated PSCs, mouse embryonic fibroblasts (MEFs) and/or hematopoietic, cardiac and endoderm progenitors
- Training for faculty, postdoctoral fellows, and students in the maintenance and the differentiation of pluripotent stem cells
- Quality tested media/reagents necessary for the maintenance as well as the differentiation of pluripotent stem cells at discounted prices
- Karotyping and banking of hESC and iPSC stocks
- Gene targeted hESC lines
- Expertise on pilot hESC projects